For the quarter ending 2026-03-31, VIR made -$29K in revenue. -$125,695K in net income. Net profit margin of 433431.03%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | -29 | 64,070 | 240 | 1,214 |
| Cost of revenue | - | 26 | -11 | 11 |
| Research and development | 108,922 | 88,349 | 151,463 | 97,509 |
| Selling, general and administrative | 23,339 | 23,616 | 22,231 | 22,283 |
| Restructuring, long-lived assets impairment and related charges, net | 0 | 0 | 0 | -172 |
| Total operating expenses | 132,261 | 111,991 | 173,683 | 119,631 |
| Loss from operations | -132,290 | -47,921 | -173,443 | -118,417 |
| Change in fair value of equity investments | -170 | -2,606 | 1,335 | -3,382 |
| Interest income | 7,189 | 7,802 | 9,363 | 10,785 |
| Other expense, net | -254 | -335 | -228 | 226 |
| Total other income | 6,765 | 4,861 | 10,470 | 7,629 |
| Loss before provision for income taxes | -125,525 | -43,060 | -162,973 | -110,788 |
| Provision for income taxes | 170 | -137 | 168 | 170 |
| Net loss | - | -42,923* | - | - |
| Net loss attributable to noncontrolling interest | - | 0* | - | - |
| Net loss | -125,695 | -42,923 | -163,141 | -110,958 |
| Basic EPS | -0.85 | -0.308 | -1.17 | -0.8 |
| Diluted EPS | -0.85 | -0.308 | -1.17 | -0.8 |
| Basic Average Shares | 147,356,811 | 139,235,134 | 138,930,173 | 138,447,469 |
| Diluted Average Shares | 147,356,811 | 139,235,134 | 138,930,173 | 138,447,469 |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)